Please assess the completion status of the following clinical trial:

Trial Title: FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to give consent to study participation~2. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye (except if the subject is monocular)~3. Cohorts 1 to 6: GA lesion(s) total size in the study eye must be ≥1.25mm2 and ≤17.5mm2.~   Cohort 7: GA lesion(s) total size in the study eye must be ≥1.25mm2~4. GA lesion(s) in the study eye must reside completely within the FAF fundus image~5. Cohorts 1 to 3: BCVA of ≤50 letters (6/36 Snellen acuity equivalent or worse) using ETDRS charts in the study eye Cohorts 4 to 7: BCVA of ≥24 letters (6/95 and 20/320 Snellen acuity equivalent or better) using ETDRS charts in the study eye~6. Aged ≥55 years~7. Able to attend all study visits and complete the study procedures~8. Women of child-bearing potential need to have a negative urine pregnancy test within two weeks prior to receiving the drug. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilised (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy)~Exclusion Criteria:~1. Have evidence or history of Choroidal Neovascularisation (CNV) in the study eye. Subjects are permitted to have CNV in the fellow eye defined as either:~   1. Non-exudative/sub-clinical fellow eye CNV identified at screening, or~  2. Known history of fellow eye CNV with either ≥2 years since diagnosis or with no active treatment required in 6 months prior to screening~2. Presence of moderate/severe non-proliferative diabetic retinopathy or worse in the study eye~3. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye~4. History of intraocular surgery in the study eye within 12 weeks prior to Screening (Visit 1). Yttrium aluminum garnet capsulotomy is permitted if performed \>10 weeks prior to Visit 1~5. Have clinically significant cataract that may require surgery during the study period in the study eye~6. Presence of moderate to severe glaucomatous optic neuropathy in the study eye; uncontrolled IOP despite the use of more than two topical agents; a history of glaucoma-filtering or valve surgery is also excluded~7. Axial myopia of greater than -8 diopters in the study eye~8. Have received any investigational product for the treatment of GA within the past 6 months or 5 half-lives (whichever is longer), other than nutritional supplements such as the Age-Related Eye Disease Study (AREDS) formula~9. Have received a gene or cell therapy at any time~10. Have a contraindication to the specified protocol corticosteroid regimen~11. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant~12. Active malignancy within the past 12 months, except for: Appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) ≥12 months~13. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study~14. Cohorts 5 to 7 only: presence of metallic objects or implanted stimulator devices in or near the head, including cochlear implants, deep brain stimulators, vagus nerve stimulators, and other implanted electrodes or stimulators

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GT005 Dose 1 (Type: EXPERIMENTAL): A single dose of GT005 will be administered via subretinal injection
- GT005 Dose 2 (Type: EXPERIMENTAL): A single dose of GT005 will be administered via subretinal injection
- GT005 Dose 3 (Type: EXPERIMENTAL): A single dose of GT005 will be administered via subretinal injection
- GT005 Dose 1, 2 or 3 (Type: EXPERIMENTAL): A single dose of GT005 will be administered via subretinal injection. This dose will be determined by dose levels determined to be tolerable in Arms 1,2 and 3
- GT005 Dose 2 with Orbit Subretinal Delivery System (Type: EXPERIMENTAL): A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
- GT005 Dose 3 with Orbit Subretinal Delivery System (Type: EXPERIMENTAL): A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
- GT005 Dose 3 with Orbit Subretinal Delivery Sysem (Type: EXPERIMENTAL): A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy